Important Content Reminder:
- The company's stock has been subject to multiple trading halts since February 10, 2026, with significant price fluctuations indicating potential market overreaction and irrational speculation. The company has issued several announcements regarding abnormal trading fluctuations and risks of potential delisting. Investors are advised to invest rationally and make cautious decisions to avoid significant investment risks in the secondary market.
- On February 26, 2026, the company received a progress report on the 2025 annual report audit from Guofu Jiaying CPA. As of the date of this report, the audit is still ongoing. Based on the audit evidence obtained and management's explanations, Guofu Jiaying found no significant inconsistencies compared to the performance forecast disclosed on January 31, 2026.
- The performance forecast disclosed on January 31, 2026, estimates the main financial indicators for 2025 as follows:
Indicator Range (in million yuan) Operating Revenue 20,000 to 25,000 Adjusted Operating Revenue 15,000 to 20,000 Total Profit -55 to -40 Net Profit Attributable to Shareholders -50 to -35 Net Profit After Non-recurring Gains and Losses -22 to -15 The company expects negative values for total profit, net profit attributable to shareholders, and net profit after non-recurring gains and losses, with both operating revenue and adjusted operating revenue below 300 million yuan. According to the Shenzhen Stock Exchange Listing Rules, the company's stock will be delisted due to financial criteria. Investors should pay attention to the associated risks and make rational decisions. - Zhongxing Caiguanghua CPA has audited the company's 2024 financial statements and issued a qualified opinion audit report (Zhongxing Caiguanghua Audit [2025] No. 207002), indicating uncertainty regarding the recoverability of investments in Jilin Wanfang Bai'ao Biotechnology Co., Ltd. As of the date of this announcement, this uncertainty remains, and there is a risk of a qualified opinion audit report for the 2025 annual report. If a qualified opinion is issued, the company's stock will be delisted according to the Shenzhen St